Особенности вакцинации от COVID-19 у пациентов онкологического профиля
Аннотация
В зарубежных периодических изданиях часто появляются сообщения о высоком риске тяжелых осложнений у онкологических пациентов при развитии COVID-19. В данной статье приведен обзор данных зарубежной литературы, включающий ряд аспектов, отражающих рекомендации по вакцинации против SARS-COV-2 пациентов с онкогематологическими заболеваниями, солидными опухолями, реципиентов гемопоэтических стволовых клеток и клеточной терапии. Несомненно, пациенты онкологического профиля относятся к группе повышенного риска тяжелого течения COVID-19, при этом текущее онкологическое заболевание не допускает задержки в терапии. В связи с этим оказание онкологической помощи во время пандемии COVID-19 стало достаточно сложной задачей, учитывая конкурирующие риски смерти от развивающегося онкологического процесса и серьезные осложнения от течения инфекции COVID-19 у людей с ослабленным иммунитетом. На сегодняшний день не существует официальных рекомендаций по проведению вакцинации против SARS-COV-2 таким пациентам. Ведущими в данном вопросе являются рекомендации зарубежных онкологических сообществ, обзор которых представлен в данной статье.
Об авторах
В. Н. Беляковский
УО «Гомельский государственный медицинский университет»
Россия
Россия
В. С. Волчек
УО «Гомельский государственный медицинский университет»
Россия
Россия
Список литературы
1. World Health Organization. Director-General’s remarks at the media briefing on 2019-nCoV on by 11 February 2020 [Electronic resource]. - Available at: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. - Date of access: 12.02.2020.
2. Yu J. SARS-CoV-2 Transmission in patients with cancer at a Tertiary Care Hospital in Wuhan, China /j. Yu, W. Ouyang, M. Chua, C. Xie // JAMA Oncology. - 2020, №. 6 (7). - Р. 1108-1110. doi.org/10.1001/jamaoncol.2020.0980.
3. Lewis M. Between Scylla and Charybdis - Oncologic Decision Making in the Time of Covid-19/ M. Lewis // The New England Journal of Medicine. - 2020. - Vol. 382. - Р. 2285-2287. doi.org/10.1056/nejmp2006588
4. Cannistra S. Challenges Faced by Medical Journals During the COVID-19 Pandemic / S. Cannistra, B. Haffty, K. Ballman // Journal of Clinical Oncology. - 2020. - Vol. 38, № 19. - р. 2206. doi.org/10.1200/jco.20.00858
5. Vaccination against SARS-COV-2 in oncology / A. Polyakov [et al.] // Oncohematology. - 2021. - Vol. 16, № 2. - Р. 70-80. (In Russ.) doi.org/10.17650/1818-8346-2021-16-2-70-80
6. Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus. Fact sheet for healthcare providers administering vaccine [Electronic resource]. - Available at: https://www.fda.gov/media/144413/download. - Date of access: 21.10.2021).
7. Emergency Use Authorization (EUA) of the Moderna COVID-19 Vaccine to prevent Coronavirus Disease 2019 (COVID-19). Factsheet for healthcare providers administering vaccine [Electronic resource]. - Available at: https://www.fda.gov/media/144637/download?utm_medium=email&utm_source=govdelivery. - Date of access: 21.10.2021.
8. US FDA. Emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) [Electronic resource]. - Available at: https://www.fda.gov/media/146304/download. - Date of access: 21.10.2021.
9. Recommendations of the National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee ) [Electronic resource]. - Available at: https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v4-0.pdf. - Date of access: 27.09.2021.
10. Recommendations of the National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee [Electronic resource]. - Available at: https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v4-0.pdf?sfvrsn=b483da2b_66. - Date of access: 09.09.2021.
11. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine / F. Polack [et al.] // The New England Journal of Medicine. - 2020. - Vol. 383. - Р. 2603-2615. doi.org/10.1056/nejmoa2034577
12. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine / L. Baden [et al.] // The New England Journal of Medicine. - 2021. - Vol. 384. - Р. 403-416. doi.org/10.1056/nejmoa2035389
13. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 /j. Sadoff [et al.] // The New England Journal of Medicine. - 2021. - Vol. 384. - Р. 2187-2201. doi.org/10.1056/nejmoa2101544
14. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients / R. Palich [et al.] // Annals of Oncology. - 2021. - Vol. 32. - Р. 1051-1053. doi.org/10.1016/j.annonc.2021.04.020
15. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors /j. Barrière [et al.] // Annals of Oncology. - 2021. - Vol. 32. - Р. 1053-1055. doi.org/10.1016/j.annonc.2021.04.019
16. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study / L. Monin [et al.] // The Lancet Oncology. - 2021. - Vol. 22. - Р. 765-778. doi.org/10.1016/s1470-2045(21)00213-8
17. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer / T. Goshen-Lago [et al.] // JAMA Oncology. - 2021. - Vol. 7. - Р. 1507-1513. doi.org/10.1001/jamaoncol.2021.2675
18. Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients / P. Heudel [et al.] // Annals of Oncology. - 2021. - Vol. 32. - Р. 1443-1444. doi.org/10.1016/j.annonc.2021.07.012
19. Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment / N. Eliakim-Raz [et al.] // JAMA Oncology. - 2021. - Vol. 7. - Р. 1716-1718. doi.org/10.1001/jamaoncol.2021.4390
20. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer / A. Massarweh [et al.] // JAMA Oncology. - 2021. - Vol. 7, № 8. - Р. 1133-1140. doi.org/10.1001/jamaoncol.2021.2155
21. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients / H. Ligumsky [et al.] // Journal of the National Cancer Institute. - 2021. - Vol. 22, № 7. - Р. 174-149. doi.org/10.1093/jnci/djab174
22. Six-Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid Tumors / I. Waldhorn [et al.] // Cancer Discovery. - 2021. - № 11. - Р. 2430-2435. doi.org/10.1158/2159-8290.cd-21-1072
23. Seroconversion rates following COVID-19 vaccination among patients with cancer / A. Thakkar [et al.] // Cancer Cell. - 2021. - Vol. 39, № 8. - Р. 1081-1090. doi.org/10.1016/j.ccell.2021.06.002
24. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies / L. Greenberger [et al.] // Cancer Cell. - 2021. - Vol. 39, № 8. - Р. 1031-1033. doi.org/10.1016/j.ccell.2021.07.012
25. Antibody Response to COVID-19 Vaccination in Adults With Hematologic Malignant Disease / T. Ollila [et al.] // JAMA Oncology. - 2021. - Vol. 7, № 11. - Р. 1714-1716. doi.org/10.1001/jamaoncol.2021.4381
26. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma / C. Perry [et al.] // Blood Advances. - 2021. - Vol. 5, № 16. - Р. 3053-3061. doi.org/10.1182/bloodadvances.2021005094
27. Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations / M. Mair [et al.] // JAMA Oncology. - 2021. - Vol. 7, № 11. - Р. 1344-1350. doi.org/10.1001/jamaoncol.2021.5437
28. Seroconversion rates following COVID-19 vaccination among patients with cancer / A. Thakkar [et al.] // Cancer Cell. - 2021. - Vol. 39, № 8. - Р. 1081-1090. doi.org/10.1016/j.ccell.2021.06.002
29. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma / C. Perry [et al.] // Blood Advances. - 2021. - Vol. 5, № 16. - Р. 3053-3061. doi.org/10.1182/bloodadvances.2021005094
30. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia / Y. Herishanu [et al.] // Blood. - 2021. - Vol. 137, № 23. - Р. 3165-3173. doi.org/10.1182/blood.2021011568
31. Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. / L. Roeker [et al.] // Leukemia. - 2020. - № 34. - Р. 3047-3049. doi.org/10.1038/s41375-020-01030-2
32. COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases / D. Baker [et al.] // Clinical and Experimental Immunology. - 2020. - Vol. 202, № 2. - Р. 149-161. doi.org/10.1111/cei.13495
33. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? / R. Houot [et al.] // European Journal of Cancer. - 2020. - Vol. 136. - Р. 4-6. doi.org/10.1016/j.ejca.2020.06.017
34. Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase / C. Mark [et al.] // Pediatric Blood and Cancer. - 2021. - Vol. 68, № 11. - Р. 292-295. doi.org/10.1002/pbc.29295
35. Vaccination and Immune Checkpoint Inhibitors: Does Vaccination Increase the Risk of Immune-related Adverse Events? A Systematic Review of Literature / A. Desage [et al.] // American Journal of Clinical Oncology. - 2021. - Vol. 44, № 3. - Р. 109-113. doi.org/10.1097/coc.0000000000000788
36. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors / B. Waissengrin [et al.] // The Lancet Oncology. - 2021. - Vol. 22, № 5. - Р. 581-583. doi.org/10.1016/s1470-2045(21)00155-8
37. Personal neoantigen vaccines induce persistent memory T-cell responses and epitope spreading in patients with melanoma / Z. Hu [et al.] // Nature Medicine. - 2021. - Vol. 27. - Р. 515-525. doi.org/10.1038/s41591-020-01206-4
38. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks /j. Hwang [et al.] // Journal of Hematology and Oncology. - 2021. - Vol. 14, № 38. - Р. 1045-1046. doi.org/10.1186/s13045-021-01046-w
39. Recommendations of the National Comprehensive Cancer Network (NCCN) COVID-19 Vaccination Advisory Committee [Electronic resource]. - Available at: https://www.nccn.org/docs/default-source/covid-19/2021_covid-19_vaccination_guidance_v4-0.pdf?sfvrsn=b483da2b_66. - Date of access: 09.09.2021.
40. Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients / V. Hall [et al.] // The New England Journal of Medicine. - 2021. - Vol. 385. - Р. 1244-1246. doi.org/10.1056/nejmc2111462
41. CDC Statement on ACIP Booster Recommendations [Electronic resource]. - Available at: https://www.cdc.gov/media/releases/2021/p0924-booster-recommendations-.html. - Date of access: 26.09.2021.
42. CDC Data and clinical considerations for additional doses in immunocompromised people [Electronic resource]. - Available at: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-07/07-COVID-Oliver-508.pdf. - Date of access: 23.07.2021.
43. US FDA. Emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) [Electronic resource]. - Available at: https://www.fda.gov/media/146304/download. - Date of access: 21.10.2021.
44. American Society of Clinical Oncology (ASCO). COVID-19 Vaccine & Patients with Cancer [Electronic resource]. - Available at: https://www.asco.org/asco-coronavirus-resources/covid-19-patient-care-information/covid-19-vaccine-patients-cancer. - Date of access: 06.01.2021.
45. update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy / N. Giesen [et al.] // European Journal of Cancer. - 2021. - Vol. 147. - Р. 154-160. doi.org/10.1016/j.ejca.2021.01.033
46. SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC) / M. Gauci [et al.] // European Journal of Cancer. - 2021. - Vol. 148. - Р. 121-123. doi.org/10.1016/j.ejca.2021.02.003
47. American College of Rheumatology. COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases [Electronic resource]. - Available at: https://www.rheumatology.org/Portals/0/Files/COVID-19-Vaccine-Clinical-Guidance-Rheumatic-Diseases-Summary.pdf. - Date of access: 04.03.2021.
48. Antibody response after second BNT162b2 dose in allogeneic HSCT recipient / R. Redjoul [et al.] // The Lancet. - 2021. - Vol. 398, № 10297. - Р. 298-299. doi.org/10.1016/s0140-6736(21)01594-4
49. Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study / F. Mozaffari [et al.] // Cancer Immunology, Immunotherapy. - 2009. - Vol. 58. - Р. 111-120. doi.org/10.1007/s00262-008-0530-5
50. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer / R. Verma [et al.] // Breast Cancer Research. - 2016. - Vol. 18, № 10. doi.org/10.1186/s13058-015-0669-x
51. Prevalence of COVID-19-related risk factors and risk of severe influenza outcomes in cancer survivors: A matched cohort study using linked English electronic health records data / H. Carreira [et al.] //EClinicalMedicine. - 2020. - Vol. 29, № 100656. doi.org/10.1016/j.eclinm.2020.100656
Рецензия
Для цитирования:
Беляковский В.Н., Волчек В.С. Особенности вакцинации от COVID-19 у пациентов онкологического профиля. Медико-биологические проблемы жизнедеятельности. 2022;(1):12-22.
For citation:
Belyakovsky V., Volchek V. FEATURES OF VACCINATION AGAINST COVID-19 IN CANCER PATIENTS. Medical and Biological Problems of Life Activity. 2022;(1):12-22. (In Russ.)
Просмотров: 51
Послать статью по эл. почте 